POINT Biopharma Global Inc. (NASDAQ:PNT) Receives $12.88 Consensus Price Target from Analysts
POINT Biopharma Global Inc. (NASDAQ:PNT – Get Free Report) has been given a consensus rating of “Hold” by the ten brokerages that are covering the stock, MarketBeat Ratings reports. Ten analysts have rated the stock with a hold recommendation. The average 1-year price objective among analysts that have issued a report on the stock in […]
More Stories
SiriusPoint (NYSE:SPNT) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded shares of SiriusPoint (NYSE:SPNT – Free Report) from a strong-buy rating to a buy rating in...
WideOpenWest (NYSE:WOW) Upgraded at Wall Street Zen
Wall Street Zen upgraded shares of WideOpenWest (NYSE:WOW – Free Report) from a sell rating to a hold rating in...
YPF Sociedad Anonima (NYSE:YPF) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen upgraded shares of YPF Sociedad Anonima (NYSE:YPF – Free Report) from a sell rating to a hold...
Wabtec (NYSE:WAB) Lowered to Hold Rating by Wall Street Zen
Wall Street Zen lowered shares of Wabtec (NYSE:WAB – Free Report) from a buy rating to a hold rating in...
Turkcell Iletisim Hizmetleri AS (NYSE:TKC) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded shares of Turkcell Iletisim Hizmetleri AS (NYSE:TKC – Free Report) from a buy rating to a...
North American Construction Group (TSE:NOA) Price Target Cut to C$34.00 by Analysts at ATB Capital
North American Construction Group (TSE:NOA – Free Report) (NYSE:NOA) had its target price reduced by ATB Capital from C$37.00 to...